Newsfeeds - Spark Newswire

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Tuesday, Sept. 14, 2021: EDIT, NSTG, IOVA, TRMB, NTDOY, TSLA, NVDA, IRDM, TTD, LC, CDXS, CLLS, CRBU, BMY

September 15, 9:45 AM

Editas Medicine (EDIT) - 13,648 Shares NanoString Technologies (NSTG) - 30,626 Iovance Biotherapeutics (IOVA) - 275,500 Trimble (TRMB) - 114,652 Nintendo (NTDOY) - 225,842 Tesla (TSLA) - 88,924 Nvidia (NVDA) -

BMY

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Monday, Sept. 13, 2021: NSTG, EDIT, TRMB, TER, IOVA, NVDA, IRDM, TTD, LC, U, PSTI, PSTG, DRNA, CRBU, CLLS, CDXS, BMY, JD, FB

By Benzinga Newsdesk

September 14, 11:22 AM

NanoString Technologies (NSTG) - 6,840 Editas Medicine (EDIT) - 84,388 Trimble (TRMB) - 63,695 Teradyne (TER) - 83,450 Iovance Biotherapeutics Inc (IOVA) - 542,589 Nvidia (NVDA)

BMY

1 minute read

Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin

By Vandana Singh

September 10, 7:43 AM

Codexis Inc (NASDAQ:CDXS) has amended and extended its agreement with Merck & Co Inc (NYSE:MRK) to license and supply a proprietary enzyme used…

CDXS

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

September 9, 4:39 PM

Gainers

CBIO

2 minute read

Codexis, Merck Amend And Extend Supply Agreement For Enzyme Used In Manufacture Of Sitagliptin

By Benzinga Newsdesk

September 9, 4:12 PM

Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and

CDXS

1 minute read

Earnings

Return on Capital Employed Insights for Codexis

By Benzinga Insights

August 31, 11:37 AM

After pulling data from Benzinga Pro it seems like during Q2, Codexis's (NASDAQ:CDXS) reported sales totaled $25.45 million. Despite a 51.0% in earnings, the company posted a loss of $4.49 million.

CDXS

5 minute read

The Daily Biotech Pulse: Early Approval For Ascendis’ Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO

By Shanthi Rexaline

August 26, 8:09 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25)

ABBV

1 minute read

Codexis Confirms Receipt of $15M Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company

By Benzinga Newsdesk

August 25, 4:13 PM

Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the Company received new purchase orders with an aggregate total value of approximately $15 million

CDXS

1 minute read

HC Wainwright & Co. Maintains Buy on Codexis, Raises Price Target to $28

By Benzinga Newsdesk

August 6, 6:33 AM

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Codexis (NASDAQ:CDXS) with a Buy and raises the price target from $27 to $28.

CDXS

1 minute read

Codexis Q2 EPS $(0.07) Beats $(0.17) Estimate, Sales $25.45M Beat $18.09M Estimate

By Benzinga Newsdesk

August 5, 5:48 PM

Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.17) by 58.82 percent. This is a 36.36 percent increase over losses of $(0.11) per share from the same

CDXS